Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M012
- Development stage
- Phase 3
- Lead developer
- Merganser Biotech
- Modality
- Peptides
- Administration
- Oral, Inhalation, Topical
01
Overview
M012 is a lead compound developed by Merganser Biotech, classified as a minihepcidin and hepcidin mimetic peptide. It is designed to treat rare hematological and iron overload diseases such as Beta Thalassemia, Polycythemia Vera, and Hemochromatosis by restricting iron absorption. The technology behind M012 originated from preclinical research at Children's Hospital of Philadelphia (CHOP) and Weill Cornell Medical College, and was licensed from UCLA. Merganser Biotech secured $28 million in Series A financing in February 2015 to advance M012 into clinical development, including Phase 1 trials.
Beyond the preview
Go deeper on M012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M012.